Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
20.84
+1.53 (7.92%)
At close: Aug 4, 2026, 4:00 PM EDT
20.44
-0.40 (-1.92%)
After-hours: Aug 4, 2026, 7:34 PM EDT
Viridian Therapeutics Employees
Viridian Therapeutics had 252 employees as of December 31, 2025. The number of employees increased by 109 or 76.22% compared to the previous year.
Employees
252
Change (1Y)
109
Growth (1Y)
76.22%
Revenue / Employee
$281,421
Profits / Employee
-$1,203,440
Market Cap
2.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 252 | 109 | 76.22% | 252 | 0 |
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Biohaven | 274 |
| Pharvaris | 134 |
| Sionna Therapeutics | 59 |
| Palvella Therapeutics | 29 |
VRDN News
- 5 weeks ago - Viridian Therapeutics price target raised to $43 from $32 at Wedbush - TheFly
- 5 weeks ago - Viridian Therapeutics price target raised to $38 from $35 at Truist - TheFly
- 5 weeks ago - Viridian Therapeutics price target raised to $35 from $34 at RBC Capital - TheFly
- 5 weeks ago - Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs - TheFly
- 5 weeks ago - Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform - TheFly
- 5 weeks ago - Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo - TheFly
- 5 weeks ago - Viridian Therapeutics Transcript: FDA announcement - Transcripts
- 5 weeks ago - Viridian Therapeutics Press release: FDA announcement - Filings